An Open-Label, Phase I Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2018
At a glance
- Drugs RG 6047 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions; First in man
- Sponsors Genentech
- 15 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Jan 2018 Planned End Date changed from 21 Dec 2018 to 30 Nov 2019.
- 05 Jan 2018 Planned primary completion date changed from 21 Dec 2018 to 30 Nov 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History